US 12,070,475 B2
Extracts for the regeneration of ligaments
Riccardo Luca Gottardi, Pittsburgh, PA (US); Benjamin Burke Rothrauff, Pittsburgh, PA (US); Rocky Sung Chi Tuan, Pittsburgh, PA (US); and Shinsuke Kihara, Pittsburgh, PA (US)
Assigned to University of Pittsburgh—Of the Commonwealth System of Higher Education, Pittsburgh, PA (US); and Ri.MED Foundation, (IT)
Appl. No. 16/970,861
Filed by University of Pittsburgh—Of the Commonwealth System of Higher Education, Pittsburgh, PA (US); and Ri.MED Foundation, Palermo (IT)
PCT Filed Feb. 22, 2019, PCT No. PCT/US2019/019119
§ 371(c)(1), (2) Date Aug. 18, 2020,
PCT Pub. No. WO2019/165185, PCT Pub. Date Aug. 29, 2019.
Claims priority of provisional application 62/633,746, filed on Feb. 22, 2018.
Prior Publication US 2020/0368289 A1, Nov. 26, 2020
Int. Cl. A61K 36/00 (2006.01); A61K 9/19 (2006.01); A61K 35/32 (2015.01); A61K 47/18 (2017.01)
CPC A61K 35/32 (2013.01) [A61K 9/19 (2013.01); A61K 47/18 (2013.01)] 19 Claims
 
1. A composition comprising:
(a) a urea-soluble fraction of decellularized, nuclease-digested anterior cruciate ligament or posterior cruciate ligament tissue prepared by:
comminuting anterior cruciate ligament or posterior cruciate ligament tissue;
decellularizing the tissue in a detergent or emulsifier;
digesting nucleic acid in the decellularized tissue by treatment of the decellularized tissue with a nuclease;
dissociating soluble components from insoluble components by exposure of the digested, decellularized tissue to urea;
fractionating the dissociated, digested, decellularized tissue to separate a urea-soluble fraction from insoluble fibrillar collagen;
collecting the urea-soluble fraction; and
removing the urea from the urea-soluble fraction; and
(b) a pharmaceutically-acceptable excipient.